U.S. stock market update: Nanobiotix SA down 10.44%

U.S. Stock Market Midday Update Nanobiotix SA fell 10.44%. According to recent important news: On September 17, Nanobiotix SA announced the Phase 1 study results of JNJ-1900 as a second-line therapy for patients with primary skin melanoma resistant to PD-1. The data showed good safety and early efficacy signals, with an objective response rate of 47.4% for all lesions. This news attracted market attention, leading to stock price fluctuations. On September 19, JNJ-1900 achieved an objective response rate of 47.4% and a disease control rate of 78.9% in patients with advanced melanoma, with a median overall survival of 14.6 months. This result further affected market sentiment, leading to a decline in stock price. No other significant news. Industry trends are positive, with significant capital flow. Stocks with High Trading Volume in the Industry Amgen rose 3.49%, with a trading volume of $904 million. Based on recent important news: On September 19, Amgen's stock price rose 2.3%, becoming the largest gainer among the Dow components, reflecting the market's positive response to its recent performance. Data source: MarketBeat. On September 20, the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanding the treatment indications for Amgen's Uplizna to include the treatment of adult immunoglobulin G4-related diseases, driving the stock price up. Data source: EMA. On September 18, analysts maintained their ratings on Amgen, with J.P. Morgan keeping a hold rating, and the market remains cautious about its future performance. Data source: TipRanks. The biotechnology industry has shown strong recent performance, with significant capital inflow. AbbVie rose 0.45%, with a trading volume of $727 million. According to recent key news: On September 17, Berenberg raised AbbVie's target price from $170 to $270, upgrading the rating from "hold" to "buy." This news drove the stock price up. On September 18, AbbVie's short interest as a percentage of float decreased by 9.38%, indicating increased bullish sentiment in the market for the stock. On September 19, significant breakthroughs in China's biopharmaceutical sector and increased international cooperation boosted market confidence in international pharmaceutical companies like AbbVie. The biopharmaceutical industry is performing strongly overall, with frequent international cooperation. Gilead Sciences rose 0.40%. According to recent important news: On September 17, Gilead Sciences' Chief Financial Officer Andrew D. Dickinson and Chief Commercial Officer Johanna Mercier sold shares of the company's common stock. This news may raise market concerns about insider confidence in the company, leading to stock price fluctuations On September 17, JP Morgan raised the target price for Gilead Sciences from $135 to $145 and maintained an "Overweight" rating. This positive analyst rating has boosted market confidence in the stock, driving its price up. On September 18, Gilead Sciences awarded Fangzhou the "Excellence Award" at a multi-channel conference in Shanghai, indicating an increase in the company's recognition in international markets, which may have a positive impact on its stock price. Market confidence in Gilead Sciences has strengthened. Stocks Ranked Among the Top by Market Capitalization in the Industry Forte Pharmaceuticals fell 0.49%, with a market capitalization of $98.7 billion. According to recent key news: On September 18, Vertex Pharmaceuticals signed a reimbursement agreement with the Italian Medicines Agency, allowing eligible patients to access the Casgevy gene editing therapy. This news may impact Forte Pharmaceuticals' market competitive position, leading to stock price fluctuations. On September 17, market analysis indicated that Vertex Pharmaceuticals' revenue outlook is relatively weak, which may lead to a decline in its stock price. This negative sentiment within the industry may affect investor confidence in Forte Pharmaceuticals. On September 17, Vertex Pharmaceuticals received an analyst rating of "Moderate Buy," but was not included in the list of the top five stocks recommended by leading analysts, which may influence investor decision-making. The gene therapy market is highly competitive and requires attention